Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-World Setting (EXPERT) Study to Assess the Efficacy of a Switch to Once-Weekly Semaglutide (Ozempic) from Another GLP-1 RA in People with Type 2 Diabetes

Next Previous
Trial Profile

A Real-World Setting (EXPERT) Study to Assess the Efficacy of a Switch to Once-Weekly Semaglutide (Ozempic) from Another GLP-1 RA in People with Type 2 Diabetes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EXPERT

Most Recent Events

  • 19 Jun 2020 New trial record
  • 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
  • 13 Jun 2020 According to a Novo Nordisk media release, results of this study (analysed data from US databases), were presented during the American Diabetes Association 80th Scientific Sessions.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top